Golden Recursion Inc. logoGolden Recursion Inc. logo
Advanced Search
Alzheon

Alzheon

Develops medicines for patients suffering from Alzheimer's disease and other neurological disorders.

All edits by  Sameeha Sulaiman 

Edits on 28 Feb, 2019
Sameeha Sulaiman
Sameeha Sulaiman edited on 28 Feb, 2019
Edits made to:
Infobox (+3 properties)
Description (+100 characters)
Article (+947 characters)
Table (+5 rows) (+10 cells) (+174 characters)
Table (+2 rows) (+7 cells) (+462 characters)
Related Topics (+1 topics)
Topic thumbnail

Alzheon

Develops medicines for patients suffering from Alzheimer's disease and other neurological disorders.

Article

Alzheon is a privately held clinical stage, biotechnology company based in Framingham, Massachusetts. It focuses on developing medications by directly addressing the underlying pathology of neurodegenerative disorders.

...

Founded in 2013, the company's lead product candidate is ALZ-801, a patented, orally administered prodrug of tramiprosate that is designed to inhibit amyloid oligomer formation, a key driver of Alzheimer's disease. The product is intended to focus on patients with mild Alzheimer's with the APOE4 genotype. It has been granted Fast Track Designation by the FDA in October 2017. Phase 3 clinical trials are planned for 2019. Alzheon's product pipeline also has ALZ-1903, a pre-clinical candidate with the potential to inhibit amyloid misfolding.

In April 2018, the company planned an $80 million IPO, but soon withdrew the offer. It re-announced later in August a $40 million IPO. However, that too was withdrawn in January 2019.

Table

Name
Role
Related Golden topics

Aidan Power

VP, Program and Portfolio Management

John Hey

Chief Scientific Officer

Kenneth Mace

VP, Finance

Martin Tolar

Founder, President & CEO

Susan Abushakra

Chief Medical Officer

Table

Title
Author
Link
Type

Alzheon Presents New Findings in APOE4/4 Homozygous Patients with Mild Alzheimer's Disease, Further Supporting Precision Medicine Approach and Planned Confirmatory Clinical Trial with ALZ-801

Web

What Happened? Alzheon Leaves IPO on the Table for the Second Time | BioSpace

Alex Keown

Web

Infobox
Related Topics
Golden logo
By using this site, you agree to our Terms & Conditions.